Shopping Cart
Remove All
Your shopping cart is currently empty
Faricimab (Synonyms: RG-7716, RG7716)
Catalog No. T78253 Copy Product Info
🥰Excellent
Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.
Faricimab
Copy Product Info🥰Excellent
Catalog No. T78253
Synonyms RG-7716, RG7716
Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.
Faricimab
Cas No. 1607793-29-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $645 | - | In Stock | |
| 5 mg | $1,690 | - | In Stock | |
| 10 mg | $2,680 | 2-4 weeks | 2-4 weeks | |
| 25 mg | $3,990 | 2-4 weeks | 2-4 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:>95% (SDS-PAGE); >95% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO. |
| In vivo | Faricimab (10 mg/kg, intraperitoneal injection, once a week, 1-5 weeks) can reduce spontaneous choroidal neovascularization (sCNV), lesion leakage area and subretinal Iba1+, CD11b+, CD45+ cell infiltration in JR5558 mice. [1] |
| Synonyms | RG-7716, RG7716 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | ANG2 & VEGFA |
| Molecular Weight | 146 kDa |
| Cas No. | 1607793-29-2 |
| Isotype | Human IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover |
| Storage | Store at low temperature | Store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Faricimab | purchase Faricimab | Faricimab cost | order Faricimab | Faricimab in vivo | Faricimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.